Royal Philips, a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Liver Fat Quantification tools as part of the latest release of its ultrasound systems EPIQ Elite and Affiniti, bringing the cost and accessibility advantages of sonography to the diagnosis of early-stage liver disease. Featured at this year’s Radiological Society of North America (RSNA) annual meeting 23 November – 2 December, Chicago, USA, the new tools will allow clinicians to track liver health.
Fatty liver disease is the most common and earliest stage of chronic liver disease. The incidence of non-alcoholic fatty liver disease (NAFLD) is increased by various risk factors, including Type 2 diabetes and obesity. It is estimated that NAFLD may be present in about 25% of the global population. NAFLD includes milder fatty liver disease, as well as more severe forms that include inflammation, a condition called Non-Alcoholic Steatohepatitis (NASH), and fibrosis. Research suggests that early intervention enables patients to adopt lifestyle changes that can help to prevent liver disease, while early assessment of fatty liver is key to potentially reversing this progression of liver disease.
With a quantitative way of measuring liver fat, it is a lot easier for us to let the referring physician know where the patient is quantitatively on the NAFLD spectrum, quoted Richard G. Barr, MD, PhD, president, Radiology Consultant, Youngstown, Ohio, U.S.A., and Medical director at Southwoods Imaging.